Theranostics
2022; 12(1):419-420.
doi:10.7150/thno.68810 This issueCite
Erratum
Inhibition of SMYD2 suppresses tumor progression by down-regulating microRNA-125b and attenuates multi-drug resistance in renal cell carcinoma: Erratum
1. Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; 2. Institute of Urology of Hubei Province, Wuhan, China 3. Department of Urinary Surgery, First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China. 4. Department of Urology, The First Affiliated Hospital of Xiamen University, Xiamen, China. 5. Department of Urology, The People's Hospital of Shenzhen City, Shenzhen, China. 6. Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, USA *These authors have contributed equally to this work
✉ Corresponding author: Hua Xu, Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Citation:
Yan L, Ding B, Liu H, Zhang Y, Zeng J, Hu J, Yao W, Yu G, An R, Chen Z, Ye Z, Xing J, Xiao K, Wu L, Xu H. Inhibition of SMYD2 suppresses tumor progression by down-regulating microRNA-125b and attenuates multi-drug resistance in renal cell carcinoma: Erratum. Theranostics 2022; 12(1):419-420. doi:10.7150/thno.68810. https://www.thno.org/v12p0419.htm
Yan, L., Ding, B., Liu, H., Zhang, Y., Zeng, J., Hu, J., Yao, W., Yu, G., An, R., Chen, Z., Ye, Z., Xing, J., Xiao, K., Wu, L., Xu, H. (2022). Inhibition of SMYD2 suppresses tumor progression by down-regulating microRNA-125b and attenuates multi-drug resistance in renal cell carcinoma: Erratum. Theranostics, 12(1), 419-420. https://doi.org/10.7150/thno.68810.
ACS
Yan, L.; Ding, B.; Liu, H.; Zhang, Y.; Zeng, J.; Hu, J.; Yao, W.; Yu, G.; An, R.; Chen, Z.; Ye, Z.; Xing, J.; Xiao, K.; Wu, L.; Xu, H. Inhibition of SMYD2 suppresses tumor progression by down-regulating microRNA-125b and attenuates multi-drug resistance in renal cell carcinoma: Erratum. Theranostics 2022, 12 (1), 419-420. DOI: 10.7150/thno.68810.
NLM
Yan L, Ding B, Liu H, Zhang Y, Zeng J, Hu J, Yao W, Yu G, An R, Chen Z, Ye Z, Xing J, Xiao K, Wu L, Xu H. Inhibition of SMYD2 suppresses tumor progression by down-regulating microRNA-125b and attenuates multi-drug resistance in renal cell carcinoma: Erratum. Theranostics 2022; 12(1):419-420. doi:10.7150/thno.68810. https://www.thno.org/v12p0419.htm
CSE
Yan L, Ding B, Liu H, Zhang Y, Zeng J, Hu J, Yao W, Yu G, An R, Chen Z, Ye Z, Xing J, Xiao K, Wu L, Xu H. 2022. Inhibition of SMYD2 suppresses tumor progression by down-regulating microRNA-125b and attenuates multi-drug resistance in renal cell carcinoma: Erratum. Theranostics. 12(1):419-420.
This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.